TD Cowen analyst Joshua Jennings lowered the firm’s price target on TransMedics (TMDX) to $120 from $190 and keeps a Buy rating on the shares. The firm said its Q1 results do not reflect the many growth drivers that should kick in soon.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Buy Rating Reiterated as Transplant Volumes Support Growth; $190 Price Target Maintained
- TransMedics signs agreement to invest in PAD Aviation
- TransMedics Maintained at Buy as CHOPS Platform Broadens Transplant Offering; $152 Price Target Reiterated
- TransMedics: Strengthening Leadership in Organ Preservation Through Rigorous Clinical Trials and Normothermic Perfusion Evidence
- William Blair healthcare IT analysts hold analyst/industry conference call